Current Pharmacological Management of Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD), a common disorder with troublesome symptoms caused by reflux of gastric contents into the esophagus, has adverse impact on quality of life. A variety of medications have been used in GERD treatment, and acid suppression therapy is the mainstay of treatment for...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2013/983653 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548067968024576 |
|---|---|
| author | Yao-Kuang Wang Wen-Hung Hsu Sophie S. W. Wang Chien-Yu Lu Fu-Chen Kuo Yu-Chung Su Sheau-Fang Yang Chiao-Yun Chen Deng-Chyang Wu Chao-Hung Kuo |
| author_facet | Yao-Kuang Wang Wen-Hung Hsu Sophie S. W. Wang Chien-Yu Lu Fu-Chen Kuo Yu-Chung Su Sheau-Fang Yang Chiao-Yun Chen Deng-Chyang Wu Chao-Hung Kuo |
| author_sort | Yao-Kuang Wang |
| collection | DOAJ |
| description | Gastroesophageal reflux disease (GERD), a common disorder with troublesome symptoms caused by reflux of gastric contents into the esophagus, has adverse impact on quality of life. A variety of medications have been used in GERD treatment, and acid suppression therapy is the mainstay of treatment for GERD. Although proton pump inhibitor is the most potent acid suppressant and provides good efficacy in esophagitis healing and symptom relief, about one-third of patients with GERD still have persistent symptoms with poor response to standard dose PPI. Antacids, alginate, histamine type-2 receptor antagonists, and prokinetic agents are usually used as add-on therapy to PPI in clinical practice. Development of novel therapeutic agents has focused on the underlying mechanisms of GERD, such as transient lower esophageal sphincter relaxation, motility disorder, mucosal protection, and esophageal hypersensitivity. Newer formulations of PPI with faster and longer duration of action and potassium-competitive acid blocker, a newer acid suppressant, have also been investigated in clinical trials. In this review, we summarize the current and developing therapeutic agents for GERD treatment. |
| format | Article |
| id | doaj-art-9378ba7680af4c0f90819285690e5adf |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-9378ba7680af4c0f90819285690e5adf2025-02-03T06:42:25ZengWileyGastroenterology Research and Practice1687-61211687-630X2013-01-01201310.1155/2013/983653983653Current Pharmacological Management of Gastroesophageal Reflux DiseaseYao-Kuang Wang0Wen-Hung Hsu1Sophie S. W. Wang2Chien-Yu Lu3Fu-Chen Kuo4Yu-Chung Su5Sheau-Fang Yang6Chiao-Yun Chen7Deng-Chyang Wu8Chao-Hung Kuo9Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDepartment of Health Management, I-Shou University, E-Da Hospital, Kaohsiung, TaiwanDepartment of Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanCancer Center, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanGastroesophageal reflux disease (GERD), a common disorder with troublesome symptoms caused by reflux of gastric contents into the esophagus, has adverse impact on quality of life. A variety of medications have been used in GERD treatment, and acid suppression therapy is the mainstay of treatment for GERD. Although proton pump inhibitor is the most potent acid suppressant and provides good efficacy in esophagitis healing and symptom relief, about one-third of patients with GERD still have persistent symptoms with poor response to standard dose PPI. Antacids, alginate, histamine type-2 receptor antagonists, and prokinetic agents are usually used as add-on therapy to PPI in clinical practice. Development of novel therapeutic agents has focused on the underlying mechanisms of GERD, such as transient lower esophageal sphincter relaxation, motility disorder, mucosal protection, and esophageal hypersensitivity. Newer formulations of PPI with faster and longer duration of action and potassium-competitive acid blocker, a newer acid suppressant, have also been investigated in clinical trials. In this review, we summarize the current and developing therapeutic agents for GERD treatment.http://dx.doi.org/10.1155/2013/983653 |
| spellingShingle | Yao-Kuang Wang Wen-Hung Hsu Sophie S. W. Wang Chien-Yu Lu Fu-Chen Kuo Yu-Chung Su Sheau-Fang Yang Chiao-Yun Chen Deng-Chyang Wu Chao-Hung Kuo Current Pharmacological Management of Gastroesophageal Reflux Disease Gastroenterology Research and Practice |
| title | Current Pharmacological Management of Gastroesophageal Reflux Disease |
| title_full | Current Pharmacological Management of Gastroesophageal Reflux Disease |
| title_fullStr | Current Pharmacological Management of Gastroesophageal Reflux Disease |
| title_full_unstemmed | Current Pharmacological Management of Gastroesophageal Reflux Disease |
| title_short | Current Pharmacological Management of Gastroesophageal Reflux Disease |
| title_sort | current pharmacological management of gastroesophageal reflux disease |
| url | http://dx.doi.org/10.1155/2013/983653 |
| work_keys_str_mv | AT yaokuangwang currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT wenhunghsu currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT sophieswwang currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT chienyulu currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT fuchenkuo currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT yuchungsu currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT sheaufangyang currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT chiaoyunchen currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT dengchyangwu currentpharmacologicalmanagementofgastroesophagealrefluxdisease AT chaohungkuo currentpharmacologicalmanagementofgastroesophagealrefluxdisease |